anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Postoperative wound infection after spinal surgery might be a challenge to manage. A wide range of procedures have been described for managing infected spinal wounds. An increasingly common procedure in the management of surgical site infections (SSI) is negative pressure wound therapy (NPWT), also known as vacuum-assisted closure. As there is a paucity of clear clinical advice the present investigation aims to update current evidence on the use of NPWT to manage postoperative SSI occurring after instrumented spine surgery.
METHODS: This systematic review was conducted according to the preferred reporting Items for systematic reviews and meta-analyses: the 2020 PRISMA statement. In January 2024, the following databases were accessed: PubMed, Web of Science, and Google Scholar. No time constraint was set for the search. All the clinical studies investigating the unique use of NPWT in treating postoperative spinal wound infections were accessed.
RESULTS: A total of 381 patients were included in the present study. Of them 52.5% (200 of 381 patients) were women. The mean age was 52.2 ± 15.2 years. The average length of the NPWT was 21.2 days (range 7-90 days).
CONCLUSION: NPWT could be a valuable adjuvant therapy for the management of SSI after spine surgery. Additional high-quality investigations are required to assess the efficacy and safety of NPWT in SSI after spine surgery, especially if combined with contraindications or risk factors, such as the presence of intraoperative CSF leak.
LEVEL OF EVIDENCE: Level IV, Systematic review.
All patients will be studied in supine position after an overnight fast, while plasma glucose levels are monitored. In the first 8 patients intravenous insulin is administered as needed, to reach target glucose levels between 5-7 mmol/l. Patients will be subjected to 10 minutes of forearm ischemia (non-dominant arm), combined with handgripping at 50% of maximal force until exhaustion. Upon reperfusion, Tc-99m-HYNIC-Annexin A5 will be injected intravenously. Targeting of annexin A5 to thenar muscle and forearm flexor muscle will be quantified as the percentage difference in radioactivity between experimental and control side. This procedure will be performed twice (randomized cross-over design), with at least 2 week interval, either with or without 10 minutes ischemia followed by 10 minutes of reperfusion prior to ischemic exercise.

Depending on the results of this study, substudies will be performed to study the effect of diazoxide (K-ATP channel opener, may mimic ischemic preconditioning), glibenclamide (K-ATP channel blocker, may inhibit ischemic preconditioning) or adenosine (infusion into brachial artery of non-dominant arm as a substitute for ischemic preconditioning).
The invention relates to a medicine composition for treating chronic cough and clinical application thereof. The medicine is prepared from extracts of radix salviae miltiorrhizae, radix astragali, dalbergia wood and Herba Houttuyniae, is used for treating chronic cough, and belongs to the field of clinical medicine research. The invention aims to provide a medicine for treating chronic cough. The medicine has the characteristics of simple production technique, quick effect taking, high curative effect, little toxic or side effect and the like, is convenient to use, and can be directly used for intravenous injection. The traditional Chinese medicine preparation is prepared from the following raw drugs in percentage by weight: 5-20% of radix salviae miltiorrhizae, 10-20% of radix astragali, 3-8% of dalbergia wood and 10-40% of Herba Houttuyniae. The invention is realized through two modes.
Participants will be randomized to 1:1:1:1 ratio to receive Treatment T- Therapeutic dose of GSK3640254 (100 mg QD) on Days 1 through 7 or Treatment ST- Supratherapeutic dose of GSK3640254 (to be determined from Part 1) on Days 1 through 7 or Treatment P- Placebo for GSK3640254 on Days 1 through 7 or Treatment M- Moxifloxacin (GSK3640254 placebo Days 1 through 6 and a single dose of Moxifloxacin \[400 mg\] on Day 7 in 4 treatment periods. There will be at least 7 days wash out period between each period.
This group will receive a single 10-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
A computational evidence platform extracts clinical concepts from medical evidence sources and creates a database of elemental diagnostic factors and elemental investigations links to medical conditions. Input from a person groups factors and investigations makes corrections and adds a ranking Elemental factors and investigations do not include information specific to their associated conditions but include synonyms and a link to a medical ontology. A patient state is determined by extracting patient known diagnostic factors and investigation results from the patient chart. These known factors and results are matched to the database and a ranking of likely conditions are output. Next-best actions per condition are output by determining factors not yet known and investigations not yet performed. Next-best actions across conditions are determined by performing a recursive tree search of the database and assuming that unknown factors are now known to generate a score for each assumption.
Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily). SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached.
Hemostasis at the radial access for subjects randomized to the VascBand™ Hemostat will be obtained in accordance to the manufacturer's instructions. The VascBand™ device will be placed proximal to the puncture site and inflated slowly while simultaneously removing the sheath, and continue to inject air (max. 18 mL) into the device until hemostasis is obtained.
PURPOSE:To obtain a cosmetic having high UV light-protecting ability, transparency and safety and excellent in water repellency and persistency by simultaneously using silicon carbide powder and an acrylic acid polymer. CONSTITUTION:This oil-in-water type emulsion cosmetic contains silicon carbide powder (the particle diameter is preferably 0.01-100mum) and an acrylic acid polymer. When a UV light-preventing agent, namely a UV light absorbent and/or a UV light-scattering agent, is, if necessary, further added, a high UV light-preventing effect is obtained. The addition of a water-soluble polymer to the cosmetic in case of necessity is preferable, because the emulsion stability is further improved. The cosmetic can be formed in various preparations such as emulsions, creams, ointments, aerosol cosmetics, and foundations. The cosmetic is stable, is excellent in the UV light-preventing effect, water repellency and persistency, and does not give a whitened appearance after applied.
NEW MATERIAL:An imidazole derivative expressed by formula I (n is 0, 1 or 2). EXAMPLE:5-(1-Methyl-2-methylthio-5-imidazolyl)methylidene-2,2-dimethyl -1,3-diox ane-4,6-dione. USE:Since the radiosensitive action is strong, the derivative is useful as a radioactive treating agent for cancer having low toxicicty. PREPARATION:A novel aldehyde compound expressed by formula II and well- known 2,2-dimethyl-1,3-dioxane-4,6-dione expressed by formula III are subjected to the Knoevenagel reaction to afford the aimed compound expressed by formula I. The compound expressed by formula II is synthesized from a well-known methoxycarbonyl-1-methyl-2-methylthioimidazole. For example, the compound expressed by formula II (n is 0) is obtained by reducing 5-methyoxycarbonyl-1- methyl-2-methylthioimidazole with a metal hydride and converting the resultant reduction product with an oxidizing agent into a 5-aldehyde derivative.
A pharmaceutical preparation is disclosed which is made up of a micelle or a vesicle each consisting of a cationic tenside with a monovalent ion and a hydrophobic cyclic or linear peptide, dispersed in a solvent whose pH value lies between pH 7-pH 8, the critical micellization concentration (cmc) lying in the range of 1.0 . 10 -7  to 7.0 . 10 -5  mol/liter. The preparation disclosed have in particular the advantage that by the increasing of the hydrophobicity of the alkyl or aryl chain or the radical at the N +  tenside both the membrane permeability is increased and furthermore the pharmaceutical active substance, in particular linear and cyclic tyrocidines (A-E), can be transferred actively into the cytosol. They thus act on the transcription level. In addition, linear and cyclic tyrocidines in particular have antiviral effects.
Methods, dressings, and systems for promoting epithelialization of a wound or other tissue are presented. The methods, dressings, and systems help form simulated rete pegs. In one instance, an epithelialization dressing is disclosed that may include a dressing body having a plurality of projections. A plurality of apertures is formed on a portion of the dressing body. The dressing helps manage fluids on the wound and the projections form cavities into which epithelial tissue migrates to from epithelial columns that function like rete pegs. Other dressings, methods, and systems are disclosed.
The spread of metastatic cancer cells poses a significant challenge in cancer treatment, making innovative approaches for early detection and diagnosis essential. Dielectrophoretic impedance spectroscopy (DEPIS), a powerful tool for cell analysis, combines dielectrophoresis (DEP) and impedance spectroscopy (IS) to separate, sort, cells and analyze their dielectric properties. In this study, we developed and built out-of-plane inkjet-printed castellated arrays to map the dielectric properties of MDA-MB-231 breast cancer cell subtypes across their metastatic potential. This was realized via modulating the expression of connexin 43 (Cx43), a marker associated with poor breast cancer prognosis and increased metastasis. We employed DEP-based trapping, followed by EIS measurements on bulk cell population, for rapid capture and differentiation of the cancer cells according to their metastatic state. Our results revealed a significant correlation between the various MDA-MB-231 metastatic subtypes and their respective dielectrophoretic and dielectric properties. Notably, cells with the highest metastatic potential exhibited the highest membrane capacitance 16.88 ± 3.24 mF m-2, followed by the less metastatic cell subtypes with membrane capacitances below 14.3 ± 2.54 mF m-2. In addition, highly metastatic cells exhibited lower crossover frequency (25 ± 1 kHz) compared to the less metastatic subtypes (≥27 ± 1 kHz), an important characteristic for cell sorting. Finally, EIS measurements showed distinct double layer capacitance (CDL) values at 1 kHz between the metastatic subgroups, confirming unique dielectric and dielectrophoretic properties correlated with the metastatic state of the cell. Our findings underscore the potential of DEPIS as a non-invasive and rapid analytical tool, offering insights into cancer biology and facilitating the development of personalized therapeutic interventions tailored to distinct metastatic stages.
The invention relates to the field of hospital equipment management, and provides a classification management method and system for hospital equipment, wherein the method comprises the following steps: based on the equipment to be classified in the hospital equipment department, the equipment can be initially classified by extracting equipment parameters and identifying main characteristics. And creating a corresponding equipment list and identification codes according to the initially classified equipment types, constructing a database structure of the hospital equipment department, and importing equipment information and maintenance records. And further classifying range identification is carried out on the equipment through the equipment parallel table and the equipment classifying rules. If the classification range of the hospital equipment department is not met, classifying the equipment into similar classifications according to the identification range and the functional characteristics. If the classification scope is met, the real-time state of the device is updated for classification management. The invention can improve the utilization rate of equipment in the hospital equipment department.
Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer). Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment.
For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Propofol infusion will be stopped at the end of surgery.
Treatment of prim. chronic polyarthritis and diabetes is effected by admin. of gamma-interferon (I). Studies have shown that treatment of rheumatic patients also afflicted with type II diabetes with (I) cures both the rheumatism and the diabetes. Patients with type I diabetes have been treated with partial success (when the beta-islet cells are still functional). It has been found that diabetics have higher antigen levels in their beta-islet cell walls than healthy subjects, stimulating prodn. of autoimmune antibodies, and that (I) blocks this immume reaction and thus inhibits degeneration of the islet cells. (I) has no side effects that might weaken the immune system.
BFPET will be administered as a single intravenous injection of up to 2 mCi (74 MBq) at rest and a single intravenous injection of up to 8mCi (296 MBq) following a stress protocol. Total amount not to exceed 10mCi (370 MBq).
Vitamin D3 is an important element in improving erectile function. However, the mechanisms of vitamin D3 remain unknown. Thus, we explored the effect of vitamin D3 on erectile function recovery after nerve injury in a rat model and investigated its possible molecular mechanisms. Eighteen male Sprague-Dawley rats were used in this study. The rats were randomly divided into three groups: the control, bilateral cavernous nerve crush (BCNC), and BCNC + vitamin D3 groups. BCNC model was established in rats by surgery. The intracavernosal pressure and the ratio of intracavernosal pressure to mean arterial pressure were utilized to evaluate erectile function. Masson trichrome staining, immunohistochemistry, terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling and western blot analysis were performed on penile tissues to elucidate the molecular mechanism. The results indicated that vitamin D3 alleviated hypoxia and suppressed the fibrosis signalling pathway by upregulating the expression of eNOS (p = 0.001), nNOS (p = 0.018) and α-SMA (p = 0.025) and downregulating the expression of HIF-1α (p = 0.048) and TGF-β1 (p = 0.034) in BCNC rats. Vitamin D3 promoted erectile function restoration by enhancing the autophagy process through decreases in the p-mTOR/mTOR ratio (p = 0.02) and p62 (p = 0.001) expression and increases in Beclin1 expression (p = 0.001) and the LC3B/LC3A ratio (p = 0.041). Vitamin D3 application improved erectile function rehabilitation by suppressing the apoptotic process through decreases in the expression of Bax (p = 0.002) and caspase-3 (p = 0.046) and an increase in the expression of Bcl2 (p = 0.004). Therefore, We concluded that vitamin D3 improved the erectile function recovery in BCNC rats by alleviating hypoxia and fibrosis, enhancing autophagy and inhibiting apoptosis in the corpus cavernosum.
Melatonin exhibits potential for pain relief and long-term safety profile. We examined the analgesic effects of oral melatonin on osteoarthritis (OA) and investigated the underlying mechanism. Using data from a UK primary care database, we conducted a cohort study in individuals with OA to compare the number of oral analgesic prescriptions and the risk of knee/hip replacement between melatonin initiators and hypnotic benzodiazepines (i.e., active comparator) initiators using quantile regression models and Cox-proportional hazard models, respectively. To elucidate causation, we examined the effects of melatonin on pain behaviors and explored several metabolites that may serve as potential regulatory agents of melatonin in the monoiodoacetate rat model of OA. Using data from another community-based cohort study, that is, the Xiangya OA Study, we verified the association between the key serum metabolite and incident symptomatic knee OA. Compared with the hypnotic benzodiazepines cohort (n = 8135), the melatonin cohort (n = 813) had significantly fewer subsequent prescriptions of oral analgesics (50th percentile: 5 vs. 7, 75th percentile: 19 vs. 29, and 99th percentile: 140 vs. 162) and experienced a lower risk of knee/hip replacement (hazard ratio = 0.47, 95% Cl: 0.30-0.73) during the follow-up period. In rats, oral melatonin alleviated pain behaviors and increased serum levels of glycine. There was an inverse association between baseline serum glycine levels and the risk of incident symptomatic knee OA in humans (n = 760). In conclusion, our findings indicate that oral melatonin shows significant potential to be a novel treatment for OA pain. The potential role of glycine in its analgesic mechanism warrants further investigation.
Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
During double-leg cycling training, people were made to do dual tasks. Dual-task: aerobic training on a bicycle ergometer + serial sevens In the dual-task condition, participants completed the exercise while simultaneously performing a series of sevens cognitive tasks. Specifically, participants were instructed to serially subtract sevens from a prescribed three-digit number (range 100-300) and read the calculations aloud while performing aerobic exercise.
PURPOSE OF REVIEW: The response to positive end-expiratory pressure (PEEP) in patients with chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation depends on the underlying pathophysiology. This review focuses on the pathophysiology of COPD, especially intrinsic PEEP (PEEPi) and its consequences, and the benefits of applying external PEEP during assisted ventilation when PEEPi is present.
RECENT FINDINGS: The presence of expiratory airflow limitation and increased airway resistance promotes the development of dynamic hyperinflation in patients with COPD during acute respiratory failure. Dynamic hyperinflation and the associated development of PEEPi increases work of breathing and contributes to ineffective triggering of the ventilator. In the presence of airflow limitation, application of external PEEP during patient-triggered ventilation has been shown to reduce inspiratory effort, facilitate ventilatory triggering and enhance patient-ventilator interaction. To minimize the risk of hyperinflation, it is advisable to limit the level of external PEEP during assisted ventilation after optimization of ventilator settings to about 70% of the level of PEEPi (measured during passive ventilation).
SUMMARY: In patients with COPD and dynamic hyperinflation receiving assisted mechanical ventilation, the application of low levels of external PEEP can minimize work of breathing, facilitate ventilator triggering and improve patient-ventilator interaction.
OBJECTIVE: Opioid and cannabinoid therapies for chronic pain conditions including neuropathic pain are controversial. Understanding patient and prescribing factors contributing to risks and implementing risk mitigation strategies optimizes outcomes.
LATEST DEVELOPMENTS: The ongoing transformation from a biomedical model of pain care toward a biopsychosocial model has been accompanied by a shift away from opioid therapy for pain, in particular for chronic pain. Opioid overdose deaths and opioid use disorder have greatly increased in the last several decades, initially because of increases in opioid prescribing and more recently associated with illicit drug use, in particular fentanyl derivatives. Opioid risk mitigation strategies may reduce risks related to opioid prescribing and tapering or discontinuation. Opioid therapy guidelines from the Centers for Disease Control and Prevention have become the consensus best practice for opioid therapy. Regulatory agencies and licensing medical boards have implemented restrictions and other mandates regarding opioid therapy. Meanwhile, interest in and use of cannabinoids for chronic pain has grown in the United States.
ESSENTIAL POINTS: Opioid therapy is generally not recommended for the chronic treatment of neuropathic pain conditions. Opioids may be considered for temporary use in patients with severe pain related to selected neuropathic pain conditions (such as postherpetic neuralgia), and only as part of a multimodal treatment regimen. Opioid risk mitigation strategies include careful patient selection and evaluation, patient education and informed consent, querying the state prescription drug monitoring programs, urine drug testing, and issuance of naloxone as potential rescue medication. Close follow-up when initiating or adjusting opioid therapy and frequent reevaluation during long-term opioid therapy is required. There is evidence for the efficacy of cannabinoids for neuropathic pain, with meaningful response rates in select patient populations.
Embodiments of the present disclosure relate to implantable cardiac sensors and associated diagnostic and treatment methods. In an exemplary embodiment, a medical system for determining a treatment regimen for a patient with a heart condition comprises a sensing device including a pressure sensor for monitoring and providing RVP information representative of right ventricle heart pressures. At least the pressure sensor is configured for implantation into a right ventricle of the patient's heart. One or more processors are coupled to receive the RVP information and configured to determine a right atrial filling pressure based on the RVP information and a left atrial filling pressure based on the RVP information. A display device displays the right atrial filling pressure and the left atrial filling pressure. In embodiments, the one or more processors determine the left and right atrial filling pressures using the right ventricular pressure as a surrogate.